Abstract
Objective: A meta-analysis was conducted to systematically review the risks of all-gradeaswell ashigh-grade rash in chronic myelogenous leukemia (CML) patients using different types of BCR-ABL inhibitors. Methods: Literature publishedbetween 2000 and April 2022 were searched using PubMed, Cochrane Library, Embase and ClinicalTrials.gov. Results: A total of12 studies were included for meta-analysis. The results showed that the incidence of all-gradeor high-grade rash associated withnew-generationBCR-ABLinhibitorshad no significant difference compared with astandard dose of imatinib. Subgroup analysis suggested that, compared with imatinib, the incidence of all grades of rash was higher in thenilotinib, bosutinib andponatinib groups. Conclusion: For CML patients treated with nilotinib, bosutinib and ponatinib, the occurrence of skin toxicity should not be ignored.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
